Aroa's Myriad Scaffold Shows 0.7% Deep Infection Rate in 411-Patient Study
Image
Auckland – September 09, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that interim results from its MASTRR Registry found deep tissue infection in just 0.7% of patients treated with its Myriad Matrix and Myriad Morcells bioscaffolds, with no adverse events causally linked to the products.
Largest published prospective bioscaffold study covers 411 patients, 474 defects
The peer-reviewed analysis, published in Advances in Therapy, tracked 411 patients and 474 soft tissue defects across 10 US centers. Aroa says this represents, to its knowledge, the largest published prospective analysis of a bioscaffold in in-patient soft tissue reconstruction.